Ensuring the Involvement of Children in the Evaluation of New Tuberculosis Treatment Regimens

1. GandhiNRMollASturmAWPawinskiRGovenderT

2006

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.

Lancet

368

1575

1580

2. RosenthalIMZhangMWilliamsKNPeloquinCATyagiS

2007

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.

PLoS Med

4

e344

doi:10.1371/journal.pmed.0040344

3. ChapuisLJiBTruffot-PernotCO'BrienRJRaviglioneMC

1994

Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice.

Am J Respir Crit Care Med

150

1355

1362

4. MatsumotoMHashizumeHTomishigeTKawasakiMTsubouchiH

2006

OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.

PLoS Med

3

e466

doi:10.1371/journal.pmed.0030466

5. StoverCKWarrenerPVanDevanterDRShermanDRArainTM

2000

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.

Nature

405

962

966

6. NikonenkoBVProtopopovaMSamalaREinckLNacyCA

2007

Drug therapy of experimental tuberculosis (TB): Improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs.

Antimicrob Agents Chemother

51

1563

1565

7. LounisNVezirisNChauffourATruffot-PernotCAndriesK

2006

Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.

Antimicrob Agents Chemother

50

3543

3547

8. RagnoRMarshallGRDi SantoRCostiRMassaS

2000

Antimycobacterial pyrroles: synthesis, anti-Mycobacterium tuberculosis activity and QSAR studies.

Bioorg Med Chem

8

1423

1432

9. NelsonLJWellsCD

2004

Global epidemiology of childhood tuberculosis.

Int J Tuberc Lung Dis

8

636

647

10. MaraisBJGrahamSMCottonMFBeyersN

2007

Diagnostic and management challenges for childhood tuberculosis in the era of HIV.

J Infect Dis

196

Suppl 1

S76

S85

11. MaraisBJGieRPSchaafHSHesselingACEnarsonDA

2006

The spectrum of disease in children treated for tuberculosis in a highly endemic area.

Int J Tuberc Lung Dis

10

732

738

12. MaraisBJGieRPSchaafHSHesselingACObiharaCC

2004

The natural history of childhood intra-thoracic tuberculosis: A critical review of literature from the pre-chemotherapy era.

Int J Tuberc Lung Dis

8

392

402

13. Tuberculosis Trials Consortium

2008

TBTC Study 26: Weekly RFP/INH for 3 mo. vs. daily INH for 9 mo. for the treatment of LTBI.

Available: http://www.clinicaltrials.gov/ct2/show/NCT00023452?term=tuberculosis%2C+rifapentine&rank=5. Accessed 17 July 2008

14. Medical Research Council

1948

Streptomycin treatment of pulmonary tuberculosis.

BMJ

1

769

782

15. FoxWEllardGAMitchisonDA

1999

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946–1986, with relevant subsequent publications.

Int J Tuberc Lung Dis

3

S231

S279

16. SchaafHSParkinDPSeifartHIWerelyCJHesselingPB

2005

Isoniazid pharmacokinetics in children treated for respiratory tuberculosis.

Arch Dis Child

90

614

618

17. DonaldPR

2007

The assessment of new anti-tuberculosis drugs for a paediatric indication.

Int J Tuberc Lung Dis

11

1162

1165

18. GibbDMDuongTTookeyPASharlandMTudor-WilliamsG

2003

Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland.

BMJ

327

1019

19. Bolton-MooreCMubiana-MbeweMCantrellRAChintuNStringerEM

2007

Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia.

JAMA

298

1888

1899

20. GortmakerSLHughesMCerviaJBradyMJohnsonGM

2001

Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1.

N Engl J Med

345

1522

1528

21. PalellaFJrDelaneyKMoormanALovelessMFuhrerJ

1998

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.

N Engl J Med

338

853

860

22. HavensPLGibbDM

2007

Increasing antiretroviral drug access for children with HIV infection.

Pediatrics

119

838

845

23. ZarHJTannenbaumEApollesPRouxPHansloD

2000

Sputum induction for the diagnosis of pulmonary tuberculosis in infants and young children in an urban setting in South Africa.

Arch Dis Child

82

305

308

24. MaraisBJHesselingACGieRPSchaafHSEnarsonDA

2006

The bacteriologic yield in children with intrathoracic tuberculosis.

Clin Infect Dis

42

e69

e71

25. ChowFEspirituNGilmanRHGutierrezRLopezS

2006

La cuerda dulce—A tolerability and acceptability study of a novel approach to specimen collection for diagnosis of paediatric pulmonary tuberculosis.

BMC Infect Dis

6

67

26. VargasDGarciaLGilmanRHEvansCTiconaE

2005

Diagnosis of sputum-scarce HIV-associated pulmonary tuberculosis in Lima, Peru.

Lancet

365

150

152

27. MaraisBJGieRPHesselingACSchaafHSLombardC

2006

A refined symptom-based approach to diagnose pulmonary tuberculosis in children.

Pediatrics

118

e1350

e1359

28. ZarHJCottonMFStraussSKarpakisJHusseyG

2007

Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: Randomised controlled trial.

BMJ

334

136

29. LindtjornBMadeboT

2001

The outcome of tuberculosis treatment at a rural hospital in southern Ethiopia.

Trop Doct

31

132

135

30. TanguisHGCaylaJAGarcia de OlallaPGJansaJMBrugalMT

2000

Factors predicting non-completion of tuberculosis treatment among HIV-infected patients in Barcelona (1987–1996).

Int J Tuberc Lung Dis

4

55

60

31. Radilla-ChavezPLaniado-LaborinR

2007

Results of directly observed treatment for tuberculosis in Ensenada, Mexico: Not all DOTS programs are created equally.

Int J Tuberc Lung Dis

11

289

292

32. HesselingACSchaafSHWestraAEWerschkullHDonaldPR

2005

Outcome of HIV-infected children with culture-confirmed tuberculosis.

Arch Dis Child

33. YeeDValiquetteCPelletierMParisienIRocherI

2003

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.

Am J Respir Crit Care Med

167

1472

1477

34. MeibohmBLaerSPanettaJCBarrettJS

2005

Population pharmacokinetic studies in pediatrics: Issues in design and analysis.

AAPS J

7

E475

E487

35. BarnesKILindegardhNOgundahunsiOOlliaroPPloweCV

2007

World Antimalarial Resistance Network (WARN) IV: Clinical pharmacology.

Malar J

6

122

36. United States Congress

2007

Food and Drug Administration Amendments Act of 2007.

HR 3580. 110th Cong. Available: http://www.fda.gov/oc/initiatives/HR3580.pdf. Accessed 17 July 2008

37. European Medicines Agency

2007

The EU Paediatric Regulation.

Available: http://www.emea.europa.eu/htms/human/paediatrics/regulation.htm. Accessed 17 July 2008

38. World Health Organization

2006

Intergovernmental Working Group on Public health, Innovation and Intellectual Property.

Available: http://www.who.int/mediacentre/events/2006/intellectual.property.meeting/en/index.html. Accessed 17 July 2008

39. FeuerC

2007

Tuberculosis research and development: A critical analysis of funding trends, 2005–2006.

Treatment Action Group. Available: http://www.aidsinfonyc.org/tag/tbhiv/tbrandd/2007tbranddreport.pdf. Accessed 17 July 2008

40. MitnickCBayonaJPalaciosEShinSFurinJ

2003

Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.

N Engl J Med

348

119

128

41. BadriMMaartensGMandaliaSBekkerLGPenrodJR

2006

Cost-effectiveness of highly active antiretroviral therapy in South Africa.

PLoS Med

3

e4

doi:10.1371/journal.pmed.0030004

42. FairallLRBachmannMOLouwagieGMvan VuurenCChikobvuP

2008

Effectiveness of antiretroviral treatment in a South African program: A cohort study.

Arch Intern Med

168

86

93